Compare Celestica Inc (CLS) vs Medtronic PLC (MDT) Price & Performance

Celestica (CLS) trades at $345.18, down 4.08% over 24 hours, with technical indicators showing a bearish trend near key support at $339. The company demonstrates strong fundamentals with Q1 2026 EPS of $2.16 beating estimates, revenue growth accelerating to 55.55% YoY, and a robust ROE of 52.45%. Recent leadership appointments and raised FY2026 revenue guidance to $19 billion reflect operational momentum amid AI and data center demand tailwinds.

Wall Street maintains a bullish outlook with 63% buy ratings and a $440.10 consensus price target, implying 27% upside. Key risks include competitive pressures in the EMS sector and execution challenges in margin expansion. The stock's high P/E of 41.82 warrants monitoring, but earnings beats and institutional confidence support a positive investment case pending Q2 results on July 28, 2026.

Medtronic (MDT) trades at $83.57, down 0.36% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $97.50. The company reported strong revenue growth to $33.54B in 2025, with net income of $4.66B and a net margin of 13.2%. Recent acquisitions, such as Scientia Vascular (PRNewsWire, 2026-06-12), and consistent earnings beats highlight operational strength and strategic expansion in medical technology.

MDT presents a compelling investment case with a 3.5% dividend yield and undervalued metrics relative to growth, but faces risks from rising debt levels and margin pressures. Analyst sentiment is strongly bullish with 58% buy ratings, though investors should monitor execution on fiscal 2027 guidance and macroeconomic headwinds impacting healthcare spending.